Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205503 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL19291677 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL25826749 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL38657149 | 0.84 | TP53 (0.64) | CNR1CNR2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL8507559 | 0.84 | TP53 (0.64) | CNR1CNR2SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4568908 | 0.82 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL4568811 | 0.82 | PPARA (0.49) | CNR1CNR2PPARGPPARA | |
| SCHEMBL4568750 | 0.81 | SLC2A1 (0.48) | CNR1CNR2PPARGPPARA | |
| SCHEMBL4568833 | 0.81 | SLC2A1 (0.48) | CNR1CNR2PPARGPPARA | |
| SCHEMBL3967742 | 0.81 | SLC2A1 (0.48) | CNR1CNR2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CNR1 2712/4885CNR2 2552/4885SMN1; SMN2 84/4885 |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CNR1 2712/4885CNR2 2552/4885SMN1; SMN2 84/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CNR1 2712/4885CNR2 2552/4885SMN1; SMN2 84/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CNR1 2237/4885CNR2 2271/4885SMN1; SMN2 42/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CNR1 2712/4885CNR2 2552/4885SMN1; SMN2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.